Clinical trial
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary…
NCT00005029 · Gynecologic Oncology Group, Other · Terminated
Key facts
| NCT number | NCT00005029 |
|---|---|
| Title | Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer |
| Official title | Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Drug |
| Interventions | topotecan hydrochloride |
| Start date | Feb 1, 2000 |
| Primary completion | Jan 1, 2004 |
| First posted | Jul 19, 2004 |
| Last update posted | Apr 12, 2018 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: